Sigalet DL, Thorne PC, Williams DC, Martin GR, Yatscoff RW. Effect of combined immunosuppressive drug therapy on small intestinal nutrient transport in the rat.
Clin Biochem 1999;
32:51-7. [PMID:
10074892 DOI:
10.1016/s0009-9120(98)00083-6]
[Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
OBJECTIVE
Prevention of rejection and preservation of graft function remain as obstacles to clinical small intestinal transplantation (SIT). This study evaluated the effects of combined immunosuppressive agents (FK506, Rapamycin, and Mycophenolate Mofetil) on intestinal function and animal well being.
METHODS
Screening for additive toxicity was done in experiment one (D1, n = 10); doses were: FK506 0.3 mg/kg/d, Rapamycin 2 mg/kg/d, and Mycophenolate Mofetil 20 mg/kg/d, orally once daily. Control animals (C1, n = 10) received equivalent vehicle. In the second phase of the experiment, the effect of an additional parenteral treatment phase was investigated, with drug treated animals (D2, n = 6) received FK506 0.3 mg/kg, Rapamycin 1 mg/kg, and Mycophenolate Mofetil 10 mg/kg sq q12h for 1 week followed by FK506 3 mg/kg, Rapamycin 1 mg/kg, and Mycophenolate Mofetil 10 mg/kg p.o. q12h for 4 weeks. Control animals (C2, n = 6) received equivalent vehicle. Parameters followed were weight gain, nutrient absorption, drug levels and nutrient transport in vitro.
RESULTS
Controls grew normally, while weight gain was significantly reduced in drug treated animals: This was paralleled by a reduction in dietary fat absorption. Drug levels were low to therapeutic for all drugs in both experiments; FK506 appeared to affect Rapamycin and Mycophenolate Mofetil metabolism, increasing levels of both as FK506 doses increased. Nutrient transport was either not effected (D1) or increased (D2).
CONCLUSIONS
We conclude that low dose combination immunosuppressive therapy inhibits weight gain, without affecting absorption of dietary energy, or adversely affecting glucose transport. We postulate a systemic metabolic cause, which requires additional investigation at the cellular level; additional studies are also required to determine if the additive immunosuppression outweigh the side effects for SIT.
Collapse